Circulating |
Serum LDH and neutrophil levels |
Colon |
LDH and neutrophil levels > ULN predict short survival |
[92] |
|
IL-8 |
Colon |
Elevated IL-8 linked to shorter PFS |
[93] |
|
Angiopoietin-2 |
Colon |
low serum levels associated with high OS |
[94] |
|
Circulating endothelial cells (CEC) |
Colon |
CEC < 65/4mL associated with longer PFS and OS |
[95–98] |
|
|
Breast |
High baseline levels associate with improved OR and PFS |
[113] |
|
VEGF plasma levels |
Breast |
<32.6 pg/mL associated with longer median TTP |
[112] |
|
|
Thyroid |
baseline concentrations ≤671 pg/mL associated with improved PFS |
[136] |
|
|
Renal |
High baseline levels associated with poor prognosis |
[151] |
|
PlGF and sVEGFR2 plasma levels and caspase 3/7 activity |
Thyroid |
Changes by more than 4.7, −1.6, and 2.1-fold, respectively, indicate response |
[136] |
|
sVEGFR2 plasma levels |
Renal |
Significant changes associated with objective tumor response |
[152, 153] |
|
Serum NGAL and VEGF levels |
Renal |
Associated with improved PFS |
[154] |
|
VCAM-1 and E-selection serum levels |
Breast |
Low levels associated with improved clinical response |
[111] |
|
sKIT plasma level |
Breast |
Decrease ≥ 50%associated with longer TTP |
[112] |
|
Serum Tg levels |
Thyroid |
Predictor for clinical outcome |
[137, 138] |
|
CAF screen |
Renal |
Predictor for PFS benefit |
[162] |
Genetic |
MMP9 C-1562T and CXCR-1 G + 2607C |
Colon |
Associated with longer PFS |
[99] |
|
VEGFR-1 319 C/A |
Colon |
A-allele has strong beneficial effect |
[100] |
|
CD133 rs2286455, rs3130, and rs2240688 SNPs |
Colon |
Associated with PFS and OS |
[103] |
|
VEGF-2578 AA and VEGF-1154 AA |
Breast |
Associated with improved OS |
[114] |
|
ccB subtype |
Renal |
Associated with poor prognosis |
[170] |
|
VEGFR-3 and CYP3A5*1 SNPs |
Renal |
Associated with increased Sunitinib toxicity |
[168] |
Physiologic |
Hypertension |
Colon |
Associated with improved PFS |
[106–108] |
|
|
Breast |
Associated with improved OS |
[113] |
Tissue |
Tumor VEGFR-3 expression |
Breast |
Overexpression associated with poor survival |
[115] |
|
Tumor BTRC expression |
Thyroid |
Mediates Sorafenib-resistance |
[142] |